Featured Executive:

Michael Rosenblatt

Michael Rosenblatt is ExecRank's Top Chief Medical Officer for 2012. Mr. Rosenblatt’s experience in leading some of the best universities in the world and his strong record of success as a mediator between policymakers, physicians, and patients at Merck & Company have propelled him to number one on this year's list.

Michael Rosenblatt is Executive Vice President & Chief Medical Officer of Merck & Company. Dr. Rosenblatt has served as Dean of Tufts University School of Medicine. He previously held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center. He served as the President of Beth Israel Deaconess Medical Center from 1999-2001 and was previously the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and Beth Israel Deaconess Medical Center. He was also a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center, a joint venture whose mission is to manage the academic enterprise and promote academic innovation.

Dean Rosenblatt has served as Director of the Harvard-MIT Division of Health Sciences and Technology, during which time he led a medical education organization for M.D., Ph.D., and M.D.-Ph.D. training jointly sponsored by Harvard and MIT. He was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he headed the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In addition, he directed drug discovery efforts in molecular biology, bone biology and calcium metabolism, virology, cancer research, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy. In Japan, he had responsibility for clinical research and development. In leading most of Merck's international research efforts, he established two major basic research institutes, one in Tsukuba, Japan, and one near Rome, Italy. He also headed Merck Research's worldwide University and Industry Relations Department.

He is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman's Award from Merck. His research is in the field of hormonal regulation of calcium metabolism, osteoporosis, and cancer metastasis to bone. His major research projects are in the design of peptide hormone antagonists (especially parathyroid hormone), isolation/characterization of receptors and mapping hormone--receptor interactions, elucidating the mechanisms by which breast and prostate cancer "home" to bone, study of the tumor-secreted parathyroid hormone-like protein, and osteoporosis and bone biology.